Results 101-120 of 146 for drugs speaker:Louise O'Reilly

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: A point was raised about reimbursement and figures that I got in response to a parliamentary question indicate that there are nine drugs that have cleared the hurdle and await approval of some form from the Health Service Executive, HSE. That ties in with many of the questions being asked this morning. People who watch this process closely do not do it for fun. They do it because they have...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: ...and not vague. When he says that we will require additional resourcing, is he saying that, as we sit here, the money is not available to fund these, so those people who are waiting for those nine drugs may as well forget waiting, because there is no point and that is not going to happen? Is it going to happen? Saying that there is a funding issue is not what people want to hear. They...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: Does Mr. Hennessy have any indication of whether it in the HSE's plans, budgets or is any movement going to be made in this regard, or will those nine drugs simply sit waiting? When Mr. Hennessy talks about effectiveness, outcomes and such, all of those hurdles have been cleared and now we find ourselves with nine drugs sitting somewhere in some sort of funding-related limbo which they may...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: A specific drug was referred to, so, verbal gymnastics aside, I do not know how Mr. Hennessy is going to be able to answer the question without addressing the drug. It was Deputy Kelly's question and related to a specific drug.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: The answer to that question is that this drug is cost effective, then.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I was surmising that part of the answer to the question is that the drug is cost effective. We can tick that box, that it is cost effective.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: We are going down the road of being very specific about one drug in this regard.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I apologise for interrupting, but the point was made on the benefit of keeping people out of hospital. When we speak about the nine drugs awaiting approval, has this been factored in by the HSE?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: When we say those nine drugs would cost €120 million over five years-----

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I have some short questions for the witnesses. On the potential for developing our own drugs, we have a thriving third level sector and a huge amount of money is being invested into skilling-up our scientists and fitting out our universities. Is there a reason why we are not developing more of our own drugs, and with the involvement of the State in the provision of those services can we not...

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: ...by representatives of the Alpha One Foundation, an advocacy group for Respreeza, and Muscular Dystrophy Ireland, an advocacy group for Translarna, to discuss the subject of funding for orphan drugs. On behalf of the committee, I welcome Ms Geraldine Kelly and Professor Gerry McElvaney of the Alpha One Foundation and Ms Clair Kelly and Mr. Richard Lodge of Muscular Dystrophy Ireland. I...

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: ...it on implementation? I would be interested in seeing if the scores are different. Reference was made to savings and the cost to the taxpayer of a non-ambulatory child versus the cost of the drug. When we questioned the HSE and the NCPE earlier, they were very clear that they took absolutely everything into account in terms of any potential savings. Could the witnesses give us their...

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: ...have met numerous advocacy groups, as we all have, and the point keeps being made that if it did actually look at the real savings involved, the conclusion could not be anything other than that the drug is cost effective. There is obviously some slippage and if we have done nothing else today, we have managed to isolate the fact that a lot of work needs to be done on the process of...

Joint Oireachtas Committee on Health: Cannabis for Medicinal Use Regulation Bill 2016: Discussion (Resumed) (13 Apr 2017)

Louise O'Reilly: ...Members' Cannabis for Medicinal Use Regulation Bill 2016. On behalf of the committee, I welcome Mr. Eugene Lennon, principal officer, and Ms Maria Egan, pharmacist, at the medicines and controlled drugs unit in the Department; Mr. Niall Byrne, registrar and chief officer of the PSI; and Dr. Cora Nestor, head of pharmacy practice development at the PSI. By virtue of section 17(2)(l) of the...

Joint Oireachtas Committee on Health: Cannabis for Medicinal Use Regulation Bill 2016: Discussion (Resumed) (13 Apr 2017)

Louise O'Reilly: .... In his opening statement, he advised that the Bill seeks to set up a parallel regulatory process and that he believes this undermines the regulatory frameworks already in place for controlled drugs. Would it be Mr. Lennon's view that the existing regulatory framework would be up to the task of regulating cannabis and that the Health Products Regulatory Authority, HPRA, would be able to...

Written Answers — Department of Health: Medicinal Products Prices (21 Mar 2017)

Louise O'Reilly: 801. To ask the Minister for Health the status of negotiations between his Department and pharmaceutical companies to secure an agreed price for the drug Savitex (details supplied). [13166/17]

Written Answers — Department of Health: Prescriptions Charges (21 Mar 2017)

Louise O'Reilly: 872. To ask the Minister for Health the estimated cost of abolishing prescription charges; the estimated cost of lowering the drug payment scheme threshold in €20 intervals; and if he will make a statement on the matter. [13432/17]

Written Answers — Department of Health: Medicinal Products Availability (28 Feb 2017)

Louise O'Reilly: 648. To ask the Minister for Health further to Parliamentary Question No. 189 of 22 February 2017 his plans to assist those persons that had been on a compassionate based programme of the drug (details supplied); if he will intervene to ensure a mechanism is put in place to ensure access is continued for those person in receipt of the drug; and if he will make a statement on the matter. [10391/17]

Written Answers — Department of Health: Medicinal Products Reimbursement (22 Feb 2017)

Louise O'Reilly: 189. To ask the Minister for Health the reason a decision was made not to reimburse Respreeza; the grounds on which this decision was made; if the HSE will be re-entering negotiations with the drug company (details supplied); the outcome for those persons that had been on a compassionate based programme of this drug; his plans to assist those persons; and if he will make a statement on the...

Written Answers — Department of Health: Medicinal Products Availability (7 Feb 2017)

Louise O'Reilly: ...manufacturers of FreeStyle Libre; if he will provide an update on this meeting; if the manufacturer has made a completed application to the HSE for reimbursement of the device under the community drugs scheme; and if he will make a statement on the matter. [5584/17]